Global HER2 Tumor Marker Testing Supply, Demand and Key Producers, 2023-2029

Global HER2 Tumor Marker Testing Supply, Demand and Key Producers, 2023-2029

The global HER2 Tumor Marker Testing market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

The global market for HER2 Tumor Marker Testing has been experiencing steady growth. This growth is primarily driven by the increasing incidence of breast cancer and the importance of HER2 status in determining treatment decisions. The market size is influenced by factors such as population aging, awareness of breast cancer screening, and advancements in diagnostic techniques. North America, particularly the United States, is a significant market for HER2 Tumor Marker Testing. The region has well-established breast cancer screening and diagnosis programs. The adoption of targeted therapies, such as Herceptin, has been prominent in this region. Europe also has a substantial market for HER2 testing, with countries like the United Kingdom, Germany, and France being key contributors. The European market is characterized by a growing emphasis on early cancer detection and personalized medicine. The Asia-Pacific region, including countries like China and India, offers growth opportunities. The increasing healthcare spending, growing awareness of breast cancer, and rising population contribute to market expansion.

HER2 Tumor Marker Testing is a diagnostic test used in oncology to assess the status of the HER2 gene and the presence of HER2 protein receptors in breast cancer and some other types of cancer, such as gastric (stomach) cancer. HER2 stands for Human Epidermal Growth Factor Receptor 2, which is a gene that encodes a protein receptor on the surface of certain cells, including breast cells. HER2 status is an important factor in determining treatment options and predicting the prognosis for individuals with specific types of cancer.

This report studies the global HER2 Tumor Marker Testing demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for HER2 Tumor Marker Testing, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of HER2 Tumor Marker Testing that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global HER2 Tumor Marker Testing total market, 2018-2029, (USD Million)

Global HER2 Tumor Marker Testing total market by region & country, CAGR, 2018-2029, (USD Million)

U.S. VS China: HER2 Tumor Marker Testing total market, key domestic companies and share, (USD Million)

Global HER2 Tumor Marker Testing revenue by player and market share 2018-2023, (USD Million)

Global HER2 Tumor Marker Testing total market by Type, CAGR, 2018-2029, (USD Million)

Global HER2 Tumor Marker Testing total market by Application, CAGR, 2018-2029, (USD Million).

This reports profiles major players in the global HER2 Tumor Marker Testing market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Abbott, Roche, Thermo Fisher Scientific, Agilent, Leica Biosystems, Biocare Medical, BioGenex, Sysmex and Abnova, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World HER2 Tumor Marker Testing market.

Detailed Segmentation:

Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global HER2 Tumor Marker Testing Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World

Global HER2 Tumor Marker Testing Market, Segmentation by Type
Immunohistochemistry (IHC)
Fluorescence In Situ Hybridization (FISH)
Silver In Situ Hybridization (SISH)
Others

Global HER2 Tumor Marker Testing Market, Segmentation by Application
Hospitals
Diagnostic Laboratories
Others

Companies Profiled:
Abbott
Roche
Thermo Fisher Scientific
Agilent
Leica Biosystems
Biocare Medical
BioGenex
Sysmex
Abnova
Novartis
InvivoGen

Key Questions Answered

1. How big is the global HER2 Tumor Marker Testing market?

2. What is the demand of the global HER2 Tumor Marker Testing market?

3. What is the year over year growth of the global HER2 Tumor Marker Testing market?

4. What is the total value of the global HER2 Tumor Marker Testing market?

5. Who are the major players in the global HER2 Tumor Marker Testing market?